|Bid||2.80 x 400|
|Ask||2.95 x 400|
|Day's Range||2.65 - 2.90|
|52 Week Range||1.50 - 3.10|
|PE Ratio (TTM)||-2,900.00|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||3.94|
Raleigh’s BioDelivery Sciences International (BDSI) is continuing on its Belbuca run since reacquiring the pain management product from Endo Pharmaceuticals earlier this year. BDSI announced Friday that Belbuca has received Health Canada approval and that it expects to launch the product in Canada early next year with a commercial partner. “BDSI has not yet announced a partner for Canada, though we have been in discussions with potential partners.
RALEIGH, N.C., June 23, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI) announced that Health Canada, the regulatory authority in Canada, has issued a Notice of Compliance (NOC) approving BELBUCA® (buprenorphine hydrochloride buccal film) for the management of pain severe enough to require daily, continuous, long-term treatment and is opioid responsive and for which alternative options are inadequate. BDSI plans to commercialize BELBUCA in Canada through a partner, and the approval is an important step in the partnering process. BELBUCA is expected to be launched in Canada in early 2018. Canada is the world's second largest per capita consumer of opioids with over 21 million prescriptions dispensed in 2014 and sales of over $880 million according to public data. According to a 2015 survey, 13% of Canadians used opioid pain relievers within the previous year. Much like in the U.S., prescription opioid abuse and misuse have reached epidemic proportions in Canada, and BELBUCA provides an alternative treatment option.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to BioDelivery Sciences International, Inc. Here are 5 ETFs with the largest exposure to BDSI-US. Comparing the performance and risk of BioDelivery Sciences International, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more (Read more...)